Medtech company Truscreen’s chief executive Martin Dillon is standing down from the role at the end of the year to return to his previous career in sports management.
TruScreen markets a cervical cancer testing device that uses opto-electronics technology acquired from the former ASX-listed
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
